Loading
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Previous close
$20.45
−$0.61 · -2.90%
After-hours
$20.7863
+$0.3363 · +1.64%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Day range
Current $20.45
52-week range
Current $20.45
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
62
Bullish
Risk
50
Elevated Risk
Momentum
63
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Day range
Current $20.45
52-week range
Current $20.45
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB8.11M0.08%10.41B USD0.44%$200.48-1.41%
AdvisorShares Psychedelics ETFPSIL1.88M4.14%48.22M USD1.84%$20.99-0.80%
iShares MSCI Ireland ETFEIRL1.11M1.46%76.1M USD0.50%$79.52-0.95%
Virtus Biotech Clinical Trials ETFBBC316.43K0.77%41.11M USD0.65%$43.10-0.43%
Invesco Nasdaq Biotechnology ETFIBBQ107.38K0.10%109.47M USD0.19%$33.6249-1.13%
ProShares Ultra Nasdaq BiotechnologyBIB49.43K0.06%88.27M USD1.19%$105.02-2.27%
First Trust IPOX Europe Equity Opportunities ETFFPXE11.01K0.23%4.75M USD0.70%$31.5427-2.53%iShares Biotechnology ETFIBBAdvisorShares Psychedelics ETFPSILiShares MSCI Ireland ETFEIRLVirtus Biotech Clinical Trials ETFBBCInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBFirst Trust IPOX Europe Equity Opportunities ETFFPXEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
